Mawdsleys selected as distributors for Morningside Pharmaceuticals Ltd

We are thrilled to announce that Morningside Pharmaceuticals Ltd have nominated Mawdsleys as distributors from 1st July 2015. 

 

Supplying quality pharmaceuticals and medical devices for over 20 years, we are very excited to be working alongside such a reputable manufacturer.

 

The Morningside Pharmaceuticals Ltd team commented

 

“Morningside are delighted to bring on board Mawdsleys to assist in the supply and distribution of our NHS contracted products. We believe that this is the start of a strategic partnership that will not only increase the flexibility of accessing Morningside Products but also build on the great level of customer service that our valued customers have come to expect.”

 

The full range of Morningside’s NHS contracted products will be available via Mawdsleys from July 1st 2015 to NHS hospitals within England, Scotland & Wales. You can order your products through your preferred route; i.e. EDI, Mawdsleys online ordering system, E-Awards, fax or by calling your local depot.

 

…Keep an eye out for a special delivery coming your way especially from us to ease your stress through the contract wave!

 

 

Other latest news
https://www.mawdsleys.co.uk/news/tillomed-laboratories-choose-mawdsleys-as-their-distributor-to-hospitals/ thumbnail image Tillomed Laboratories choose Mawdsleys as their distributor to hospitals

Mawdsleys are delighted to be assisting Tillomed Laboratories in bringing their injectable products to market (September 2017). We will be distributing CMU contracted products to English hospitals and products with special prices to Scotland, Wales and Northern Ireland:     Description: Carmustine Injection Vial 100mg Pack: 100mg PIP Code: 7936438 EAN Code: 008902319061371 Description: Cidofovir…

Read more
https://www.mawdsleys.co.uk/news/mawdsleys-and-oncoscience-launch-a-named-patient-program-for-cimaher-nimotuzumab-in-the-uk-and-ireland/ thumbnail image Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher®

Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.   Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of…

Read more
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.